In order to substantiate the hypothesis suggesting differences of TGF-β1 plasma concentrations in the early preclinical stages of cognitive decline in individuals with DS, we assessed this anti-inflammatory cytokine in individuals with DS, distinguishing those with or without AD-related cognitive decline. This evidence concerns the gene TGFB1 and Dravet syndrome.